Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL J LEONARD IV

Allopathic & Osteopathic Physicians Pediatrics

NPI
1801058243
CMS profile
500103
Location
HASTINGS, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$13.39

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $13.39 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Sobi, Inc $13.39 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL J LEONARD IV

NPI 1801058243 · CMS profile ID 500103

Allopathic & Osteopathic Physicians / Pediatrics

HASTINGS, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801058243?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801058243?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801058243?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1801058243?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $13.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sobi, Inc $13.3905/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851494897 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $13.39 1
PY2023 $33.08 3
PY2024 $109.51 4
PY2025 $27.88 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $168,874.99 57
PY2024 Principal investigator $439,732.84 105
PY2023 Recipient $7,049.40 6
PY2023 Principal investigator $530,880.36 269
PY2022 Principal investigator $1,225,410.93 120
PY2021 Principal investigator $1,389,610.75 61
PY2020 Principal investigator $5,537.42 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $439.45 12/31/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940401097
Principal investigator 1 Merck Sharp & Dohme LLC $656.63 12/31/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940401099
Principal investigator 1 Merck Sharp & Dohme LLC $12,988.69 12/31/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940401109
Principal investigator 1 SANOFI PASTEUR INC. $775.00 12/30/2022 Non-covered Recipient Entity
Meridian Clinical Research,LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 935555793
Principal investigator 1 ModernaTX, Inc. $1,817.10 12/23/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572227
Principal investigator 1 GlaxoSmithKline, LLC. $2,705.58 12/21/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049849
Principal investigator 1 ModernaTX, Inc. $11,214.45 12/21/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572223
Principal investigator 1 ModernaTX, Inc. $2,941.20 12/16/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963572813
Principal investigator 1 ModernaTX, Inc. $1,470.15 12/15/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572177
Principal investigator 1 ModernaTX, Inc. $490.05 12/15/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572181
Principal investigator 1 ModernaTX, Inc. $931.50 12/15/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572187
Principal investigator 1 ModernaTX, Inc. $1,158.30 12/15/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572209
Principal investigator 1 ModernaTX, Inc. $897.75 12/15/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572211
Principal investigator 1 ModernaTX, Inc. $4,488.75 12/15/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572213
Principal investigator 1 ModernaTX, Inc. $745.20 12/15/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572217
Principal investigator 1 ModernaTX, Inc. $5,101.79 12/14/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572189
Principal investigator 1 ModernaTX, Inc. $11,834.91 12/14/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572193
Principal investigator 1 ModernaTX, Inc. $2,338.81 12/14/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572205
Principal investigator 1 ModernaTX, Inc. $490.05 12/14/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572231
Principal investigator 1 ModernaTX, Inc. $1,360.12 12/14/2022 Non-covered Recipient Entity
Meridian Clinical Research
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 963573079
Principal investigator 1 ModernaTX, Inc. $71.59 12/14/2022 Non-covered Recipient Entity
Meridian Clinical Research
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 963573081
Principal investigator 1 ModernaTX, Inc. $391.63 12/13/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963572159
Principal investigator 1 Merck Sharp & Dohme LLC $43,175.00 12/12/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 940401725
Principal investigator 1 ModernaTX, Inc. $67,897.76 12/09/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572195
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,380.10 12/08/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 3 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933402987
Principal investigator 1 ModernaTX, Inc. $5,214.31 12/07/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572185
Principal investigator 1 ModernaTX, Inc. $3,800.72 12/01/2022 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963572175
Principal investigator 1 ModernaTX, Inc. $186.30 11/25/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419067
Principal investigator 1 ModernaTX, Inc. $1,751.23 11/25/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963419079
Principal investigator 1 ModernaTX, Inc. $14,015.23 11/23/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419045
Principal investigator 1 GlaxoSmithKline, LLC. $3,292.01 11/18/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049799
Principal investigator 1 ModernaTX, Inc. $1,551.15 11/18/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419055
Principal investigator 1 ModernaTX, Inc. $8,926.20 11/16/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419015
Principal investigator 1 ModernaTX, Inc. $363.15 11/16/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419039
Principal investigator 1 ModernaTX, Inc. $8,841.15 11/16/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419061
Principal investigator 1 ModernaTX, Inc. $9,798.30 11/14/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419021
Principal investigator 1 ModernaTX, Inc. $10,208.70 11/14/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419027
Principal investigator 1 ModernaTX, Inc. $24,307.76 11/14/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419033
Principal investigator 1 ModernaTX, Inc. $7,500.00 11/14/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 963420061
Principal investigator 1 ModernaTX, Inc. $1,960.20 11/09/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963419049
Principal investigator 1 ModernaTX, Inc. $827.45 11/09/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963419073
Principal investigator 1 ModernaTX, Inc. $1,000.00 11/02/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 963419487
Principal investigator 1 ModernaTX, Inc. $307.80 10/28/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963418985
Principal investigator 1 ModernaTX, Inc. $1,421.55 10/28/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963418991
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/28/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 963535399
Principal investigator 1 ModernaTX, Inc. $46,761.10 10/26/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963418979
Principal investigator 1 ModernaTX, Inc. $10,000.00 10/26/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 963535401
Principal investigator 1 ModernaTX, Inc. $5,000.00 10/26/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 963535403
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/26/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 963535405
Principal investigator 1 GlaxoSmithKline, LLC. $6,415.58 10/19/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049879
Principal investigator 1 ModernaTX, Inc. $36,052.18 10/19/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963418973
Principal investigator 1 ModernaTX, Inc. $2,291.07 10/14/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418955
Principal investigator 1 ModernaTX, Inc. $3,630.96 10/07/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963418967
Principal investigator 1 ModernaTX, Inc. $5,064.90 10/07/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963418997
Principal investigator 1 ModernaTX, Inc. $17,909.84 10/05/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963418961
Principal investigator 1 ModernaTX, Inc. $2,297.10 09/28/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963490993
Principal investigator 1 ModernaTX, Inc. $3,391.20 09/26/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490883
Principal investigator 1 ModernaTX, Inc. $13,431.08 09/23/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490899
Principal investigator 1 ModernaTX, Inc. $4,110.00 09/23/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963491009
Principal investigator 1 ModernaTX, Inc. $117.73 09/19/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490833
Principal investigator 1 ModernaTX, Inc. $509.09 09/19/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490843
Principal investigator 1 ModernaTX, Inc. $928.44 09/19/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490849
Principal investigator 1 GlaxoSmithKline, LLC. $3,366.68 09/16/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 944049809
Principal investigator 1 ModernaTX, Inc. $2,403.00 09/16/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490869
Principal investigator 1 ModernaTX, Inc. $92,066.63 09/16/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490963
Principal investigator 1 ModernaTX, Inc. $4,558.39 09/14/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963491013
Principal investigator 1 ModernaTX, Inc. $9,672.75 09/09/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490893
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,101.75 09/08/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 3 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ? 6 to <18 Years of Age No dispute reported 06/30/2026 933399833
Principal investigator 1 ModernaTX, Inc. $250.20 09/06/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490839
Principal investigator 1 ModernaTX, Inc. $1,833.30 09/06/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490863
Principal investigator 1 ModernaTX, Inc. $750.00 09/02/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418907
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/02/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418913
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/02/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418919
Principal investigator 1 ModernaTX, Inc. $3,500.00 09/02/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418925
Principal investigator 1 ModernaTX, Inc. $5,000.00 09/02/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418931
Principal investigator 1 ModernaTX, Inc. $7,500.00 09/02/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418943
Principal investigator 1 ModernaTX, Inc. $10,000.00 09/02/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418949
Principal investigator 1 ModernaTX, Inc. $2,775.60 09/01/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490879
Principal investigator 1 ModernaTX, Inc. $1,574.91 08/26/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490859
Principal investigator 1 ModernaTX, Inc. $5,149.95 08/24/2022 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 963418937
Principal investigator 1 ModernaTX, Inc. $1,173.25 08/24/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963490983
Principal investigator 1 GlaxoSmithKline, LLC. $8,407.41 08/19/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 944049791
Principal investigator 1 ModernaTX, Inc. $17,041.66 08/19/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490903
Principal investigator 1 ModernaTX, Inc. $67.50 08/12/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490829
Principal investigator 1 GlaxoSmithKline, LLC. $5,884.79 08/10/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 944049889
Principal investigator 1 GlaxoSmithKline, LLC. $1,765.44 08/05/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 944049817
Principal investigator 1 GlaxoSmithKline, LLC. $7,944.47 08/05/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 944049839
Principal investigator 1 GlaxoSmithKline, LLC. $1,765.44 08/05/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 944049859
Principal investigator 1 GlaxoSmithKline, LLC. $2,353.91 08/05/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 944049869
Principal investigator 1 ModernaTX, Inc. $4,008.81 08/05/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963490999
Principal investigator 1 ModernaTX, Inc. $35,741.52 08/03/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490933
Principal investigator 1 ModernaTX, Inc. $25.65 07/27/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490823
Principal investigator 1 ModernaTX, Inc. $24,506.01 07/27/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490919
Principal investigator 1 ModernaTX, Inc. $12,322.55 07/15/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490974
Principal investigator 1 GlaxoSmithKline, LLC. $6,681.60 06/24/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
EFFICACY, SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HERPES ZOSTER S No dispute reported 06/30/2026 944049897
Principal investigator 1 ModernaTX, Inc. $1,683.31 06/24/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963490989
Principal investigator 1 GlaxoSmithKline, LLC. $5,873.14 06/17/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 944049827
Principal investigator 1 ModernaTX, Inc. $4,019.93 06/10/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963491003
Principal investigator 1 Amgen Inc. $542.72 06/08/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
Ph3 Pediatric CM Study No dispute reported 06/30/2026 942843397
Principal investigator 1 Amgen Inc. $608.64 06/08/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 942843699
Principal investigator 1 ModernaTX, Inc. $43,064.15 06/08/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490949
Principal investigator 1 ModernaTX, Inc. $1,346.91 06/03/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490853
Principal investigator 1 ModernaTX, Inc. $2,641.00 06/03/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490873
Principal investigator 1 ModernaTX, Inc. $18,063.12 06/03/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490909
Principal investigator 1 Amgen Inc. $77.25 05/26/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 942844085
Principal investigator 1 ModernaTX, Inc. $1,173.25 05/25/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 963490979
Principal investigator 1 ModernaTX, Inc. $45,573.10 05/04/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490955
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $10,000.00 04/14/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 3 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933384467
Principal investigator 1 ModernaTX, Inc. $18,546.65 04/13/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490913
Principal investigator 1 ModernaTX, Inc. $30,805.94 04/13/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490923
Principal investigator 1 Amgen Inc. $9,000.00 03/23/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
P1b children/adolescents w/ migraine No dispute reported 06/30/2026 942841833
Principal investigator 1 ModernaTX, Inc. $99,643.05 03/09/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490969
Principal investigator 1 ModernaTX, Inc. $4,145.61 03/04/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490889
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,500.00 03/03/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 3 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 933381693
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,000.00 03/03/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 3 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 933381701
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $500.00 03/03/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 3 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 933381709
Principal investigator 1 ModernaTX, Inc. $36,046.71 01/28/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490939
Principal investigator 1 ModernaTX, Inc. $35,704.80 01/12/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490929
Principal investigator 1 ModernaTX, Inc. $37,947.68 01/12/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490943
Principal investigator 1 ModernaTX, Inc. $76,765.76 01/12/2022 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963490959